Bayer says its rivaroxaban drug is significantly more effective than the current standard therapy in preventing blood clots after knee surgery, according to phase III trial results.
Subscribe to our email newsletter
Rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head comparison with Sanofi-Aventis’ Lovenox, known generically as enoxaparin, the current standard of care.
Patients treated with rivaroxaban demonstrated a 49% relative risk reduction in the composite primary endpoint of deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and all-cause mortality compared to those treated with enoxaparin.
A 62% reduction of risk for developing major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) – the secondary endpoint of the trial – was observed in the patients treated with rivaroxaban. Rivaroxaban also demonstrated a similarly low rate of major bleeding compared to enoxaparin (0.6% and 0.5%, respectively).
Rivaroxaban is an investigational, oral, once-daily direct factor Xa inhibitor. It is an anticoagulant – a drug designed to prevent and treat blood clots – in advanced clinical development for the prevention and treatment of thrombosis in acute and chronic settings.
The drug is being jointly developed by Johnson & Johnson Pharmaceutical R&D, and Bayer HealthCare AG.
The companies plan to submit regulatory filings for the prevention of VTE in orthopaedic surgery in late 2007 in Europe and in 2008 in the US.